Volume 4, Issue 1 , Pages 17-27, January 2011
Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: A review
Electroconvulsive therapy (ECT) and ablative neurosurgical procedures are established interventions for treatment-resistant depression (TRD), but their use may be limited in part by neuropsychological adverse effects. Additional neuromodulation strategies are being developed that aim to match or exceed the efficacy of ECT/ablative surgery with a better neurocognitive side effect profile. In this review, we briefly discuss the neurocognitive effects of ECT and ablative neurosurgical procedures, then synthesize the available neurocognitive information for emerging neuromodulation therapies, including repetitive transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, vagus nerve stimulation, and deep brain stimulation. The available evidence suggests these procedures may be more cognitively benign relative to ECT or ablative neurosurgical procedures, though further research is clearly needed to fully evaluate the neurocognitive effects, both positive and negative, of these novel neuromodulation interventions.
Keywords: major depression, neuromodulation, neuropsychology, antidepressant treatment
To access this article, please choose from the options below
This work was supported in part by the Summer Undergraduate Research Experience (SURE) at Emory program (J.L.M.), KL2 RR024983 (S.M.M.; PI: Milton Packer) and K23 MH077869 (PEH). J.L.M. has received grant funding from Emory College's Scholarly Inquiry and Research at Emory (SIRE) program. S.M.M. has received grant funding from NARSAD, National Institutes of Mental Health (NIMH), and the National Center for Research Resources (NCRR). P.E.H. has received grant funding from the Dana Foundation, Greenwall Foundation, NARSAD, National Institute of Mental Health, National Institutes of Health Loan Repayment Program, Neuronetics, Northstar, Stanley Medical Research Institute, and Woodruff Foundation.
P.E.H. is or has been a consultant for AvaCat Consulting, AstraZeneca, Oppenheimer & Co, St. Jude Medical Neuromodulation, Shaw Science, Tetragenex; he has received honoraria from CME Outfitters, Inc. (Cyberonics), CME LLC, Inc. (Bristol-Myers Squibb), and Letters and Sciences (Bristol-Myers Squibb).
PII: S1935-861X(10)00016-1
doi:10.1016/j.brs.2010.01.005
© 2011 Elsevier Inc. All rights reserved.
Volume 4, Issue 1 , Pages 17-27, January 2011
